William P. “Bill” Reddick

Chief Financial Operator

Bill is a finance professional with a strong analytical skill set and extensive experience in equity research, private investing and company formation.

Prior to joining ArunA Biomedical as Chief Financial Officer, Bill co-lead managment at Reddick & Murphy Consulting, a financial consulting practice. RMC primarily functions as contract CFO, conducts financial analysis of investment opportunities and conducts pre-diligence for clients considering scaling capital or M&A transactions. The firm specializes in transformative events (M&A, asset dispositions, strategic shifts) and offers a full range of services to help management understand investment cases and earnings dynamics.

Prior to RMC, Bill was a founder and CFO of Celtaxsys, Inc. a biopharmaceutical company located in Atlanta, Georgia. The Company is focused on development of anti-inflammatory drugs for Cystic Fibrosis and Pulmonary Arterial Hypertension. Bill had various management roles with the Company from inception through mid-2016 and raised $85M to fund clinical development of a novel small molecule drug platform. The Company is currently completing a Phase 2 clinical trial with data expected in the second quarter of 2018.

Prior to Celtaxsys, Bill was founder, chief analyst and syndicate manager for Masters Capital Management, a long/ short hedge fund located in Atlanta, Georgia. Over the last 22 years the fund has had CAGR in excess of 26% and currently manages $980M.

Bill started his career at Arthur Andersen & Company and was a senior accountant and audit specialist in physician practice M&A and Medicare reimbursement optimization.